Design Therapeutics, Inc. (DSGN) News
Filter DSGN News Items
DSGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DSGN News Highlights
- For DSGN, its 30 day story count is now at 2.
- Over the past 23 days, the trend for DSGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest DSGN News From Around the Web
Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDesign Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Positive Signs As Multiple Insiders Buy Design Therapeutics StockUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic UpdatePratik Shah Takes Helm as CEO, Company Eyes Long-Term Growth |
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic |
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday! |
Why Shares of Design Therapeutics Are Plummeting on TuesdayShares of Design Therapeutics (NASDAQ: DSGN) were down more than 69% as of 2:15 p.m. ET on Tuesday. It also announced phase 1 results for DT-216 to treat FA, a rare, inherited disease that causes progressive damage to the nervous system. The disease affects more than 5,000 people in the U.S. and has no approved therapies yet. |
Redfin upgraded, CSSE downgraded: Wall Street's top analyst callsRedfin upgraded, CSSE downgraded: Wall Street's top analyst calls |
4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per CitiHere is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Urban Outfitters, Keysight Technologies, Design Therapeutics, and Avid Technology. Citi downgraded Urban Outfitters (NASDAQ:URBN) to Neutral from Buy with a price target of $40.00 (from $36.00), as reported in real time on InvestingPro. Citi expects the company to beat Q2 earnings estimates and provide strong guidance next Tuesday but believes the company's risk/reward now looks balanced. |
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsInitial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and Report Data in the First Half of 2025 IND Submission for FECD GeneTAC™ Program On-track for the Second Half of 2023 $303.1 Million in Cash and Securities Expected to Support Operating Runway through 2026 CARLS |